Gandolfi et al1 have studied the influence on intraocular pressure of injecting 1 mg of mitomycin subconjunctivally into the blind eye of volunteers with glaucoma. The protocol had the approval of the Institutional Review Board of the University of Parma in Italy, and Gandolfi et al reported that each of the subjects participating in the investigation was aware of the possible adverse effect of the treatment.
Some years ago a survey was published2 in which the carcinogenic property of mitomycin in rodents was mentioned. Furthermore, in Martindale: The Extra Pharmacopoeia,3 it is stated that mitomycin is a highly toxic antibiotic with antineoplastic properties and that it acts as an alkylating agent. Such substances inhibit DNA synthesis by cross-linkage and cause breakage of single-stranded DNA.4 Another name for the substance is "mutamycin" indicating that it is mutagenic and that it induces chromosomal aberrations. One, therefore, wonders whether
Gebhardt DOE. Decrease of Intraocular Pressure After Subconjunctival Injection of Mitomycin in Human Glaucoma. Arch Ophthalmol. 1996;114(10):1298. doi:10.1001/archopht.1996.01100140498037